NASDAQ: ANNX | Healthcare / Biotechnology / USA |
1.90 | -0.1900 | -9.09% | Vol 518.56K | 1Y Perf -68.24% |
Oct 4th, 2023 16:00 DELAYED |
BID | 1.85 | ASK | 1.99 | ||
Open | 2.02 | Previous Close | 2.09 | ||
Pre-Market | - | After-Market | 1.96 | ||
- - | 0.06 3.16% |
Target Price | 18.57 | Analyst Rating | Moderate Buy 1.63 | |
Potential % | 877.37 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | 100/100/-20 | Value Ranking | — - | |
Insiders Value % 3/6/12 mo. | 100/100/89 | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12 mo. | 100/100/98 | Income Ranking | — - | |
Price Range Ratio 52W % | -1.41 | Earnings Rating | — | |
Market Cap | 101.15M | Earnings Date | 2nd Nov 2023 | |
Alpha | -0.03 | Standard Deviation | 0.24 | |
Beta | 0.69 |
Today's Price Range 1.902.10 | 52W Range 1.987.65 |
Summary:
Sell
Technical Indicators: | Neutral |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -17.03% | ||
1 Month | -29.10% | ||
3 Months | -46.93% | ||
6 Months | -52.74% | ||
1 Year | -68.24% | ||
3 Years | -93.15% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -55.21 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -46.54 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -49.40 | |||
Return on invested Capital Q | -14.53 | |||
Return on invested Capital Y | -40.39 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-1.40 | ||||
0.87 | ||||
- | ||||
- | ||||
-2.40 | ||||
-2.55 | ||||
0.87 | ||||
5.47 | ||||
-8 139 720.00 | ||||
Forward PE | - | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
13.30 | ||||
13.60 | ||||
0.11 | ||||
0.13 | ||||
- | ||||
Leverage Ratio | 1.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.00 | ||||
0.00 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | -0.54 | -0.47 | 12.96 |
Q01 2023 | -0.52 | -0.52 | 0.00 |
Q04 2022 | -0.52 | -0.48 | 7.69 |
Q03 2022 | -0.87 | -0.51 | 41.38 |
Q02 2022 | -0.94 | -0.96 | -2.13 |
Q01 2022 | -1.00 | -0.92 | 8.00 |
Q04 2021 | -0.90 | -0.97 | -7.78 |
Q03 2021 | -0.88 | -0.93 | -5.68 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Next Report Date | 2nd Nov 2023 |
Estimated EPS Next Report | -0.50 |
Estimates Count | 5 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 518.56K |
Shares Outstanding | 53.24K |
Shares Float | 32.39M |
Trades Count | 5.27K |
Dollar Volume | 1.03M |
Avg. Volume | 324.78K |
Avg. Weekly Volume | 246.61K |
Avg. Monthly Volume | 365.03K |
Avg. Quarterly Volume | 362.71K |
Annexon Inc. (NASDAQ: ANNX) stock closed at 1.9 per share at the end of the most recent trading day (a -9.09% change compared to the prior day closing price) with a volume of 518.56K shares and market capitalization of 101.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 38 people. Annexon Inc. CEO is Douglas Love.
The one-year performance of Annexon Inc. stock is -68.24%, while year-to-date (YTD) performance is -63.25%. ANNX stock has a five-year performance of %. Its 52-week range is between 1.98 and 7.65, which gives ANNX stock a 52-week price range ratio of -1.41%
Annexon Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 0.87, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -46.54%, a ROC of -49.40% and a ROE of -55.21%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Annexon Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. Annexon Inc.’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Annexon Inc. is Moderate Buy (1.63), with a target price of $18.57, which is +877.37% compared to the current price. The earnings rating for Annexon Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Annexon Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Annexon Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 23.86, ATR14 : 0.19, CCI20 : -167.28, Chaikin Money Flow : 0.10, MACD : -0.16, Money Flow Index : 65.48, ROC : -17.39, RSI : 33.86, STOCH (14,3) : 13.66, STOCH RSI : 0.00, UO : 46.69, Williams %R : -86.34), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Annexon Inc. in the last 12-months were: Douglas Love (Sold 6 571 shares of value $38 564 ), Jennifer Lew (Sold 1 908 shares of value $12 035 ), Love Douglas (Sold 6 571 shares of value $38 572 ), Michael Overdorf (Sold 1 645 shares of value $10 368 ), Muneer A. Satter (Buy at a value of $17 999 994), Overdorf Michael (Sold 1 645 shares of value $10 364 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005; ANX007; and ANX009.
CEO: Douglas Love
Telephone: +1 650 822-5500
Address: 180 Kimball Way, South San Francisco 94080, CA, US
Number of employees: 38
Tue, 08 Aug 2023 10:25 GMT Annexon Biosciences (ANNX) Gets a Buy from H.C. Wainwright
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.